Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis

A Study to Assess Whether Etrolizumab is a Safe and Effective Treatment for Participants With Moderately to Severely Active Crohn's Disease (CD)

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Open-Label Extension and Safety Study for Patients With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144

Triple Combination Therapy in High Risk Crohn's Disease (CD)

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients

Entyvio (Vedolizumab) Long Term Safety Study

Open-Label Extension of RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis

Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver (NAFL) or Nonalcoholic Steatohepatitis (NASH)

Vedolizumab Subcutaneous Long-Term Open-Label Extension Study

Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year

A Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn's Disease